abrdn plc bought a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 211,068 shares of the company's stock, valued at approximately $3,768,000. abrdn plc owned about 0.63% of Grail as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Douglas Lane & Associates LLC acquired a new stake in Grail during the 4th quarter worth about $3,034,000. A. D. Beadell Investment Counsel Inc. acquired a new stake in shares of Grail during the fourth quarter valued at approximately $430,000. FNY Investment Advisers LLC purchased a new stake in shares of Grail in the 4th quarter valued at approximately $26,000. 180 Wealth Advisors LLC purchased a new stake in shares of Grail in the 4th quarter valued at approximately $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management acquired a new stake in shares of Grail in the fourth quarter worth $387,000.
Insider Activity
In related news, CFO Aaron Freidin sold 30,452 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the transaction, the chief financial officer now directly owns 268,277 shares in the company, valued at $3,761,243.54. This represents a 10.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Grail Trading Up 33.9 %
Shares of NASDAQ:GRAL traded up $13.32 during trading on Thursday, reaching $52.58. The stock had a trading volume of 5,007,840 shares, compared to its average volume of 1,243,353. The stock has a fifty day simple moving average of $22.67 and a two-hundred day simple moving average of $17.58. Grail, Inc. has a 52 week low of $12.33 and a 52 week high of $52.85.
Grail (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($3.94) EPS for the quarter. The company had revenue of $28.65 million for the quarter. Equities analysts anticipate that Grail, Inc. will post -65.16 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have commented on GRAL shares. Guggenheim began coverage on Grail in a research note on Thursday, October 17th. They issued a "neutral" rating on the stock. Morgan Stanley assumed coverage on Grail in a research report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price target for the company. Finally, Wolfe Research began coverage on Grail in a report on Friday, November 15th. They set a "peer perform" rating on the stock.
Check Out Our Latest Stock Report on GRAL
About Grail
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
